2014 Interventions of Interest:

  • Sulfonylureas
  • Insulin
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Glucagon-like peptide-1 (GLP-1) receptor agonists
  • Continuous blood glucose monitoring

The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have diabetes, of whom 95% have the type 2 form.

The key findings of the report, along with CEPAC’s votes, suggest that high value treatment options, such as NPH insulin (intermediate-acting human insulin), may be underutilized in many patients.

For questions, please contact info@icer.org.


Final Documents

Below you will find the final documents from the assessment review process:

Public CommentsDownload
Final Evidence Report and Meeting SummaryDownload